# Keryx Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/keryx-biopharmaceuticals

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.keryx.com
- Latest round: Series B (Dec 1, 1999)
- Investors on record: 1

## About

Keryx Biopharmaceuticals is a biopharmaceutical company specializing in innovative therapies for chronic kidney disease, focusing on enhancing patient care through effective and targeted medical solutions.Keryx Biopharmaceuticals develops therapies for chronic kidney disease. The company was founded as an independent entity and is headquartered in New York, US. In July 2000, Keryx completed its IPO, raising USD 46 mn, marking a significant milestone in its funding journey.Keryx Biopharmaceuticals is committed to developing and commercializing innovative treatments for patients with chronic kidney disease (CKD). Its primary focus is on FDA-approved products that address the complications associated with CKD, ultimately aiming to improve patient quality of life. The company primarily serves the North American healthcare market, targeting healthcare professionals, patients, and caregivers involved in CKD treatment.In 2017, Keryx Biopharmaceuticals reported a revenue of USD 60.64 mn. The company’s revenue model is based on selling its proprietary biopharmaceutical products directly to healthcare providers and institutions, with pricing structured through established contracts that influence reimbursement and accessibility.Keryx Biopharmaceuticals aims to leverage its recent IPO funding of USD 46 mn to enhance its product offerings and expand into new markets. The company plans to focus on the development of new therapies and potential market entries into international regions by 2025. These initiatives are part of Keryx's strategy to improve patient outcomes and expand its reach in the chronic kidney disease sector.

## Funding rounds

- Series B, Dec 1, 1999 — Sonostar Ventures

## Investors

- Sonostar Ventures (https://capitalatlas.ai/funds/sonostar-ventures) — Series B